The abstract is read at the publisher; the summary is JClub's.
A label-free interferometry protocol enables high-speed quantitative phase imaging of thousands of 3D-bioprinted tumor organoids per experiment at single-organoid resolution, including drug response profiling.
- Why it matters: Organoid drug screening needs organoid-level readouts to capture heterogeneity and rare phenotypes, but ECM-embedded cultures are hard to image and bulk assays miss single-organoid dynamics.
- What they did: Cells are bioprinted into a temperature-sensitive ECM as thin, flat, square patterns in 96-well plates, then high-speed live cell interferometry with machine learning quantifies biomass, growth kinetics, and drug response profiles.
- The result: The approach automatically generates plates with thousands of organoids, resolves growth and drug-response heterogeneity, and identifies predictive features for therapeutic decision-making, with a protocol completion time of 2 weeks or less.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.